Beam Therapeutics Inc. (BEAM) Stock Price & How to Invest

Beam Therapeutics (NASDAQ: BEAM) develops precision genetic medicines using base editing, a technique it helped invent that rewrites a single letter of DNA without cutting both strands of the double helix, aiming for more precise fixes than first-generation CRISPR. Its pipeline spans risto-cel (formerly BEAM-101) for sickle cell disease, with a biologics license application targeted as early as year-end 2026, plus BEAM-302 for alpha-1 antitrypsin deficiency, and BEAM-301 and BEAM-304 for rare liver-mediated genetic diseases. The company also runs collaborations with partners including Pfizer and Eli Lilly, which supply most of its reported revenue through upfront payments and milestones.

As a clinical-stage company, Beam has no approved product and posts steep operating losses funded by a large cash balance, so the investment picture is about pipeline progress rather than profitability. Reported revenue is lumpy collaboration income, not product sales, and the stock tends to move sharply on trial data, regulatory updates, and the broader gene-editing sector's sentiment. The bull case is that base editing proves best-in-class across several high-value indications and converts to approvals; the bear case is that trials disappoint, timelines slip, or dilution mounts before any therapy reaches the market.

Beam is pre-commercial and deeply unprofitable, so it carries the full binary risk of a clinical-stage biotech: a single failed trial, safety signal, or regulatory setback can reset the stock. Gene and cell therapies face complex manufacturing, long timelines, and uncertain pricing and reimbursement even after approval. Despite a large cash balance, sustained losses mean future capital raises and shareholder dilution are plausible. The company competes in a crowded gene-editing field, and sector-wide sentiment can pressure the shares regardless of Beam's own progress. There is no guarantee any program reaches the market.

13 analysts publish price targets on BEAM, averaging $52.31 against a $25.52 price as of August 2026, or +105.0%. The published targets run from $26.00 to $80.00, a wide spread, and the ratings split 13 buy, 2 hold, 0 sell. Over the last six months there have been 3 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BEAM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Beam Therapeutics Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Risto-cel sickle cell path to filing. Risto-cel (formerly BEAM-101) is Beam's most advanced program, an autologous cell therapy for sickle cell disease. The most optimistic published target, $80.00, assumes this works close to its best case.

The case against. Beam is pre-commercial and deeply unprofitable, so it carries the full binary risk of a clinical-stage biotech: a single failed trial, safety signal, or regulatory setback can reset the stock. The most pessimistic target, $26.00, is roughly what BEAM is worth if this bites instead.

Read the full bull and bear case on BEAM, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Beam Therapeutics Inc.'s investor relations page or your broker.

• Market cap: ~$3.6B
• Revenue (Q1 2026): ~$31.7M
• Revenue (Q1 2025): ~$7.5M
• Net loss (Q1 2026): ~$94.3M
• Cash & securities: ~$1.2B
• Cash runway: into ~mid-2029

Beam's revenue is collaboration and milestone income, not product sales, so it is lumpy and not comparable to a profitable company's top line. With no approved therapy and heavy R&D spending, the company runs large net losses funded by its cash pile. Valuation therefore reflects the market's probability-weighted view of the pipeline rather than current earnings.

If you want BEAM exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses BEAM naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to BEAM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get BEAM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ARKG), which spreads the position across many companies. Or build it into a focused thematic portfolio, so BEAM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BEAM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Beam is a well-capitalized but pre-revenue gene-editing bet whose worth swings on clinical data rather than earnings, so it fits a high-risk, long-horizon slice of a portfolio.

Whether BEAM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BEAM a buy or a sell?, and where the stock could go from here in the BEAM stock forecast.

For income investors, whether BEAM pays a dividend and how the payout looks is covered in does BEAM pay a dividend? And to weigh BEAM against a peer, read the full side-by-side comparisons: BEAM vs CRSP and BEAM vs NTLA.